Bristol-Myers Squibb Analyst Price Targets

Wall Street analyst price targets and consensus rating for Bristol-Myers Squibb (BMY).

Price Target Range — 13 Quarters

Analyst Consensus — 24 Analysts

9Buy

14Hold

1Sell

Consensus RatingNeutral# Analysts24Avg. Consensus PT$62Upside to Avg. PT+3.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 8, 2026	Cantor Fitzgerald	Carter Gould	PT Cut	Neutral	$59→$53
Oct 7, 2026	Morgan Stanley	Terence Flynn	PT Raise	Underweight	$40→$41
Oct 5, 2026	Leerink Partners	David Risinger	Downgrade	Outperform→Market Perform	$73→$59
Sep 16, 2026	Piper Sandler	David Amsellem	PT Raise	Overweight	$75→$82
Sep 10, 2026	HSBC	Rajesh Kumar	PT Raise	Hold	$60→$65
Aug 5, 2026	Argus Research	Jasper Hellweg	Upgrade	Hold→Buy	$75
Aug 3, 2026	Citigroup	Geoff Meacham	PT Raise	Neutral	$66→$70
Jul 31, 2026	RBC Capital	Trung Huynh	PT Raise	Sector Perform	$60→$64
Jul 31, 2026	JP Morgan	Chris Schott	PT Raise	Overweight	$67→$73
Jul 31, 2026	Cantor Fitzgerald	Carter Gould	PT Raise	Neutral	$54→$59
Jul 31, 2026	Wells Fargo	Mohit Bansal	PT Raise	Equal-Weight	$60→$65
Jul 31, 2026	Guggenheim	Seamus Fernandez	PT Raise	Buy	$72→$75
Jul 31, 2026	Truist Securities	Robyn Karnauskas	Maintained	Buy	$65→$70
Jul 10, 2026	B of A Securities	Tim Anderson	PT Cut	Buy	$67→$66
Jul 6, 2026	Cantor Fitzgerald	Carter Gould	Maintained	Neutral	$54
Apr 9, 2026	B of A Securities	Tim Anderson	PT Cut	Buy	$68→$67
Apr 8, 2026	Guggenheim	Seamus Fernandez	Maintained	Buy	$72
Apr 8, 2026	Cantor Fitzgerald	Carter Gould	PT Raise	Neutral	$45→$54
Mar 17, 2026	HSBC	Rajesh Kumar	PT Raise	Hold	$53→$60
Feb 25, 2026	RBC Capital	Trung Huynh	Initiate	Sector Perform	$60

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Cantor Fitzgerald Maintains Neutral on Bristol-Myers Squibb, Lowers Price Target to $53

Cantor Fitzgerald analyst Carter Gould maintains Bristol-Myers Squibb (NYSE:BMY) with a Neutral and lowers the price target from $59 to $53.

Benzinga Newsdesk

PRO
Morgan Stanley Maintains Underweight on Bristol-Myers Squibb, Raises Price Target to $41

Morgan Stanley analyst Terence Flynn maintains Bristol-Myers Squibb (NYSE:BMY) with a Underweight and raises the price target from $40 to $41.

Benzinga Newsdesk

PRO
Leerink Partners Downgrades Bristol-Myers Squibb to Market Perform, Lowers Price Target to $59

Leerink Partners analyst David Risinger downgrades Bristol-Myers Squibb (NYSE:BMY) from Outperform to Market Perform and lowers the price target from $73 to $59.

Benzinga Newsdesk

This $3 Biotech Could Be Worth $11.45, Analyst Says

William Blair initiates Perspective Therapeutics (NYSE: CATX) at Outperform, citing its strong radiopharmaceutical platform.

Vandana Singh

PRO
Piper Sandler Reiterates Overweight on Bristol-Myers Squibb, Raises Price Target to $82

Piper Sandler analyst David Amsellem reiterates Bristol-Myers Squibb (NYSE:BMY) with a Overweight and raises the price target from $75 to $82.

Benzinga Newsdesk

PRO
HSBC Maintains Hold on Bristol-Myers Squibb, Raises Price Target to $65

HSBC analyst Rajesh Kumar maintains Bristol-Myers Squibb (NYSE:BMY) with a Hold and raises the price target from $60 to $65.

Benzinga Newsdesk

Bristol-Myers Squibb Co

Bristol-Myers Squibb Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Cantor Fitzgerald Maintains Neutral on Bristol-Myers Squibb, Lowers Price Target to $53

PRO
Morgan Stanley Maintains Underweight on Bristol-Myers Squibb, Raises Price Target to $41

PRO
Leerink Partners Downgrades Bristol-Myers Squibb to Market Perform, Lowers Price Target to $59

This $3 Biotech Could Be Worth $11.45, Analyst Says

PRO
Piper Sandler Reiterates Overweight on Bristol-Myers Squibb, Raises Price Target to $82

PRO
HSBC Maintains Hold on Bristol-Myers Squibb, Raises Price Target to $65

People Also Watch

People Also Watch

Bristol-Myers Squibb Co

Bristol-Myers Squibb Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROCantor Fitzgerald Maintains Neutral on Bristol-Myers Squibb, Lowers Price Target to $53

PROMorgan Stanley Maintains Underweight on Bristol-Myers Squibb, Raises Price Target to $41

PROLeerink Partners Downgrades Bristol-Myers Squibb to Market Perform, Lowers Price Target to $59

This $3 Biotech Could Be Worth $11.45, Analyst Says

PROPiper Sandler Reiterates Overweight on Bristol-Myers Squibb, Raises Price Target to $82

PROHSBC Maintains Hold on Bristol-Myers Squibb, Raises Price Target to $65

People Also Watch

People Also Watch

PRO
Cantor Fitzgerald Maintains Neutral on Bristol-Myers Squibb, Lowers Price Target to $53

PRO
Morgan Stanley Maintains Underweight on Bristol-Myers Squibb, Raises Price Target to $41

PRO
Leerink Partners Downgrades Bristol-Myers Squibb to Market Perform, Lowers Price Target to $59

PRO
Piper Sandler Reiterates Overweight on Bristol-Myers Squibb, Raises Price Target to $82

PRO
HSBC Maintains Hold on Bristol-Myers Squibb, Raises Price Target to $65